110 related articles for article (PubMed ID: 2190532)
1. [Chemotherapy in cancer of the prostate].
D'Acremont B; Gattegno B; Cohen L; Fiatte P; Lucaks B; Thibault P
Ann Urol (Paris); 1990; 24(2):87-95. PubMed ID: 2190532
[TBL] [Abstract][Full Text] [Related]
2. [Response criteria for prostatic cancer treated by chemotherapy or antiandrogenic therapy].
Akaza H; Usami M; Kotake T; Matsumura Y; Moriyama N; Imai K; Fuse H; Isaka S; Yamanaka H; Matsumoto K
Hinyokika Kiyo; 1987 Jun; 33(6):894-904. PubMed ID: 3673839
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy: is it effective in treatment of prostatic cancer?
Murphy GP
Urology; 1984 Nov; 24(5 Suppl):41-7. PubMed ID: 6388094
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy of hormone-unresponsive prostatic cancer and its metastatic foci].
Kotake T
Gan To Kagaku Ryoho; 1982 Mar; 9(3):387-96. PubMed ID: 6764105
[TBL] [Abstract][Full Text] [Related]
5. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for advanced prostate cancer: docetaxel and beyond.
Dreicer R
Hematol Oncol Clin North Am; 2006 Aug; 20(4):935-46, x. PubMed ID: 16861124
[TBL] [Abstract][Full Text] [Related]
8. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
[TBL] [Abstract][Full Text] [Related]
9. How effective is cytotoxic chemotherapy for disseminated prostatic carcinoma?
Eisenberger MA; Kennedy P; Abrams J
Oncology (Williston Park); 1987 Jun; 1(4):59-71. PubMed ID: 3079482
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
11. The role of systemic cytotoxic therapy for prostate cancer.
Chang SS; Kibel AS
BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
[TBL] [Abstract][Full Text] [Related]
12. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
13. The case for adjuvant therapy for prostate cancer.
Glodé LM
J Urol; 2006 Dec; 176(6 Pt 2):S30-3. PubMed ID: 17084163
[TBL] [Abstract][Full Text] [Related]
14. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
Miglietta L; Cannobbio L; Boccardo F
Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy of breast and prostate cancer.
Manni A
Endocrinol Metab Clin North Am; 1989 Jun; 18(2):569-92. PubMed ID: 2663486
[TBL] [Abstract][Full Text] [Related]
16. [Cancer of the prostate: current status of chemotherapy].
Bollak C; Bergerat JP; Jacquemin D
Bull Cancer; 1986; 73(1):61-4. PubMed ID: 3535934
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapies for non-metastatic prostate cancer: review of the literature.
Jereczek-Fossa BA; Curigliano G; Orecchia R
Onkologie; 2009 Jun; 32(6):359-63. PubMed ID: 19521126
[TBL] [Abstract][Full Text] [Related]
18. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer.
Roach M
Eur Urol; 1997; 32 Suppl 3():48-54. PubMed ID: 9267785
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.
Andriole GL
Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
